itraconazole ^{Xi Nghezi} (Q411229)

Kusuka e Wikidata

Jump to navigation Jump to search

group of stereoisomers ^{Xi Nghezi}

Language	Label	Description	Also known as
Xitsonga	No label defined	No description defined
Xi Nghezi	itraconazole	group of stereoisomers	R-51211 ITCZ

Statements

group of stereoisomers ^{Xi Nghezi}

0 references

subclass of ^{Xi Nghezi}

essential medicine ^{Xi Nghezi}

0 references

azole ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

27 Nyenyenyani 2018

medication ^{Xi Nghezi}

0 references

chemical structure ^{Xi Nghezi}

Itraconazole2DACS.svg
591 × 382; 24 KB

media legend ^{Xi Nghezi}

struktura itrakonazolu bez określonej konfiguracji jednego centrum stereogenicznego (Xi Polixi)

structure of itraconazole with undefined configuration of one stereocentre (Xi Nghezi)

0 references

704.239307 dalton

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

chemical formula ^{Xi Nghezi}

C₃₅H₃₈Cl₂N₈O₄

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

canonical SMILES ^{Xi Nghezi}

CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

isomeric SMILES ^{Xi Nghezi}

CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

World Health Organisation international non-proprietary name ^{Xi Nghezi}

itraconazole (Xi Nghezi)

1 reference

stated in ^{Xi Nghezi}

ChEMBL ^{Xi Nghezi}

ChEMBL ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Sunguti 2016

medical condition treated ^{Xi Nghezi}

vulvovaginal candidiasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

oral candidiasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

coccidioidomycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

aspergillosis ^{Xi Nghezi}

2 references

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

stated in ^{Xi Nghezi}

Drug Indications Extracted from FAERS ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

2 Nhlangula 2018

Leyiximeniyasisi

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

dermatomycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

chronic mucocutaneous candidiasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

paracoccidioidomycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

blastomycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

candidiasis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

cryptococcosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

neutropenia ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

sporotrichosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

histoplasmosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

fungal infectious disease ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

tinea ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

entomophthoramycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

onychomycosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

13 N'wendzamhala 2016

allergic bronchopulmonary aspergillosis ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Drug Indications Extracted from FAERS ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

2 Nhlangula 2018

significant drug interaction ^{Xi Nghezi}

domperidone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

ergotamine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

ergotism ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

vincristine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hepatotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

simvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hepatotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

atorvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hepatotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

lomitapide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hepatotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

carbamazepin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hepatotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

quetiapine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

buprenorphine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

central respiratory depression ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

buprenorphine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

alfentanil ^{Xi Nghezi}

side effect ^{Xi Nghezi}

central respiratory depression ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fluticasone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

Decreased circulating cortisol level ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fentanyl ^{Xi Nghezi}

side effect ^{Xi Nghezi}

depressed level of consciousness ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

fentanyl ^{Xi Nghezi}

side effect ^{Xi Nghezi}

central respiratory depression ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

pimozide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

vincristine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

paralytic ileus ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

vincristine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

toxic encephalopathy ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

eplerenone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hyperkalemia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

eplerenone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hypotension ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

nifedipine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

sinus bradycardia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

nifedipine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

hypotension ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

nifedipine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

acute kidney injury ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

digoxin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

heart arrhythmia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

digoxin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

nausea ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

digoxin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

vomiting ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sirolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

leukopenia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sirolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

anemia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sirolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

thrombocytopenia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sirolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

Achor-Smith syndrom ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sirolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

diarrhea ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

torsades de pointes ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

pulseless electrical activity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

disopyramide ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sunitinib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

ranolazine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

felodipine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cardiotoxicity ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

nilotinib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

panobinostat ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

simvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

rhabdomyolysis ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

simvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

muscular disease ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

atorvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

rhabdomyolysis ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

atorvastatin ^{Xi Nghezi}

side effect ^{Xi Nghezi}

muscular disease ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

probably ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

efavirenz ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

cyclosporine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

kidney failure ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

cyclosporine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

cholestasis ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

cyclosporine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

paresthesia ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

sufentanil ^{Xi Nghezi}

side effect ^{Xi Nghezi}

central respiratory depression ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

dronedarone ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

crizotinib ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

eliglustat ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

ivabradine ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

midazolam ^{Xi Nghezi}

side effect ^{Xi Nghezi}

central respiratory depression ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

established ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

tacrolimus ^{Xi Nghezi}

side effect ^{Xi Nghezi}

long QT syndrome ^{Xi Nghezi}

1 reference

sourcing circumstances ^{Xi Nghezi}

hypothetically ^{Xi Nghezi}

stated in ^{Xi Nghezi}

A reference set of clinically relevant adverse drug-drug interactions ^{Xi Nghezi}

legal status (medicine) ^{Xi Nghezi}

boxed warning ^{Xi Nghezi}

1 reference

reference URL ^{Xi Nghezi}

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

title ^{Xi Nghezi}

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (Xi Nghezi)

pregnancy category ^{Xi Nghezi}

Australian pregnancy category B3 ^{Xi Nghezi}

1 reference

imported from Wikimedia project ^{Xi Nghezi}

English Wikipedia ^{Xi Nghezi}

US pregnancy category C ^{Xi Nghezi}

1 reference

imported from Wikimedia project ^{Xi Nghezi}

English Wikipedia ^{Xi Nghezi}

LiverTox likelihood score ^{Xi Nghezi}

LiverTox toxicity likelihood category B ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

LiverTox ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

8 Dzivamusoko 2021

reference URL ^{Xi Nghezi}

https://www.ncbi.nlm.nih.gov/books/n/livertox/Itraconazole

last update ^{Xi Nghezi}

17 Mudyaxihi 2017

subject has role ^{Xi Nghezi}

xenobiotic-transporting ATPase inhibitor ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

5 Nyenyankulu 2018

cytochrome P-450 CYP3A inhibitors ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

antifungal ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

14-alpha demethylase inhibitor ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Medical Subject Headings ^{Xi Nghezi}

MeSH descriptor ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

15 Nyenyankulu 2018

different from ^{Xi Nghezi}

Itrizole ^{Xi Nghezi}

0 references

Ntlawa wa Commons

Itraconazole

0 references

Identifiers

InChI ^{Xi Nghezi}

InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

InChIKey ^{Xi Nghezi}

VHVPQPYKVGDNFY-ZPGVKDDISA-N

2 references

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

stated in ^{Xi Nghezi}

ChEBI release 2020-09-01 ^{Xi Nghezi}

CAS Registry Number ^{Xi Nghezi}

2 references

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

InChIKey ^{Xi Nghezi}

VHVPQPYKVGDNFY-ZPGVKDDISA-N

stated in ^{Xi Nghezi}

CAS Common Chemistry ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

9 Dzivamusoko 2021

reference URL ^{Xi Nghezi}

https://commonchemistry.cas.org/detail?cas_rn=84625-61-6

ChemSpider ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChemSpider ^{Xi Nghezi}

ChemSpider ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

PubChem CID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

PubChem ^{Xi Nghezi}

PubChem CID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

ChEBI ID ^{Xi Nghezi}

mapping relation type ^{Xi Nghezi}

exact match ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

ChEMBL ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChEMBL ^{Xi Nghezi}

ChEMBL ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

ITRACONAZOLE (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

UniChem compound ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

UniChem ^{Xi Nghezi}

SPLASH ^{Xi Nghezi}

splash10-0a4i-0112100900-c45b863fbc00a8c449b4

0 references

HSDB ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Hazardous Substances Data Bank ^{Xi Nghezi}

HSDB ID ^{Xi Nghezi}

publication date ^{Xi Nghezi}

28 Nhlangula 2019

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

10 Mudyaxihi 2021

DSSTox substance ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard ^{Xi Nghezi}

DSSTOX compound identifier ^{Xi Nghezi}

0 references

LiverTox ID ^{Xi Nghezi}

0 references

NSC number ^{Xi Nghezi}

0 references

EC number ^{Xi Nghezi}

617-596-9

1 reference

stated in ^{Xi Nghezi}

ECHA Substance Infocard database ^{Xi Nghezi}

ECHA Substance Infocard ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

27 N'wendzamhala 2018

title ^{Xi Nghezi}

(2R*,4S*)-1-sec-Butyl-4-{4-[4-(4- {[cis-2-(2,4-dichlorphenyl)- 2-(1,2,4-triazol-1-ylmethyl)- 1,3-dioxolan-4-yl]methoxy}phenyl) piperazin-1-yl]phenyl}- 4,5-dihydro-1,2,4-triazol-5-on (Xi Nghezi)

quotation ^{Xi Nghezi}

CAS no.: 84625-61-6 (Xi Nghezi)

ECHA Substance Infocard ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ECHA Substance Infocard database ^{Xi Nghezi}

ECHA Substance Infocard ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

27 N'wendzamhala 2018

title ^{Xi Nghezi}

(2R*,4S*)-1-sec-Butyl-4-{4-[4-(4- {[cis-2-(2,4-dichlorphenyl)- 2-(1,2,4-triazol-1-ylmethyl)- 1,3-dioxolan-4-yl]methoxy}phenyl) piperazin-1-yl]phenyl}- 4,5-dihydro-1,2,4-triazol-5-on (Xi Nghezi)

quotation ^{Xi Nghezi}

CAS no.: 84625-61-6 (Xi Nghezi)

CosIng number ^{Xi Nghezi}

0 references

AICS Chemical ID (BEING DELETED) ^{Xi Nghezi}

0 references

ATC code ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

DrugBank ^{Xi Nghezi}

DrugBank ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

publication date ^{Xi Nghezi}

17 Hukuri 2015

World Health Organisation international non-proprietary name numeric ID ^{Xi Nghezi}

0 references

MeSH descriptor ID ^{Xi Nghezi}

subject named as ^{Xi Nghezi}

Itraconazole

0 references

MeSH tree code ^{Xi Nghezi}

D03.383.129.799.550

0 references

D03.383.606.530

0 references

RxNorm ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

26 Nyenyenyani 2018

DrugBank ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

DrugBank ^{Xi Nghezi}

DrugBank ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

Human Metabolome Database ID ^{Xi Nghezi}

1 reference

based on heuristic ^{Xi Nghezi}

inferred from InChIKey ^{Xi Nghezi}

UNII ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

DrugBank ^{Xi Nghezi}

DrugBank ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

Itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

MedlinePlus drug identifier ^{Xi Nghezi}

0 references

PatientsLikeMe treatment ID ^{Xi Nghezi}

0 references

NDF-RT ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

NDF-RT ^{Xi Nghezi}

NDF-RT ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

ITRACONAZOLE (Xi Nghezi)

retrieved ^{Xi Nghezi}

19 Sunguti 2016

Probes And Drugs ID ^{Xi Nghezi}

0 references

KEGG ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

ChEBI ^{Xi Nghezi}

ChEBI ID ^{Xi Nghezi}

language of work or name ^{Xi Nghezi}

title ^{Xi Nghezi}

itraconazole (Xi Nghezi)

retrieved ^{Xi Nghezi}

4 Nhlangula 2016

IEDB Epitope ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Immune Epitope Database and Analysis Resource ^{Xi Nghezi}

IEDB Epitope ID ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

1 Nyenyankulu 2022

CAB ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

CAB Thesaurus ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

6 Dzivamusoko 2020

DeCS ID ^{Xi Nghezi}

0 references

electronic Essential Medicines List medicine ID ^{Xi Nghezi}

0 references

Encyclopedia of China (Third Edition) ID ^{Xi Nghezi}

subject named as ^{Xi Nghezi}

伊曲康唑

0 references

Freebase ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

Freebase Data Dumps ^{Xi Nghezi}

publication date ^{Xi Nghezi}

28 Nhlangula 2013

Microsoft Academic ID ^{Xi Nghezi}

0 references

OpenAlex ID ^{Xi Nghezi}

1 reference

stated in ^{Xi Nghezi}

OpenAlex ^{Xi Nghezi}

retrieved ^{Xi Nghezi}

26 Sunguti 2022

reference URL ^{Xi Nghezi}

https://docs.openalex.org/download-snapshot/snapshot-data-format

Quora topic ID ^{Xi Nghezi}

0 references

Römpp online ID ^{Xi Nghezi}

1 reference

imported from Wikimedia project ^{Xi Nghezi}

German Wikipedia ^{Xi Nghezi}

UNSPSC Code ^{Xi Nghezi}

0 references

WikiProjectMed ID ^{Xi Nghezi}

0 references

WordNet 3.1 Synset ID ^{Xi Nghezi}

03593855-n

1 reference

stated in ^{Xi Nghezi}

GF WordNet ^{Xi Nghezi}

Sitelinks

Wikipedia(32 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Itraconazole

ku suka e "https://www.wikidata.org/w/index.php?title=Q411229&oldid=2136208710"